Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ELF1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ELF1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ELF1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ELF1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ELF1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ELF1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ELF1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ELF1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ELF1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ELF1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ELF1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003424912 | Prostate | Tumor | negative regulation of cellular amide metabolic process | 80/3246 | 273/18723 | 6.33e-07 | 1.32e-05 | 80 |
GO:004670014 | Prostate | Tumor | heterocycle catabolic process | 117/3246 | 445/18723 | 1.11e-06 | 2.10e-05 | 117 |
GO:004427015 | Prostate | Tumor | cellular nitrogen compound catabolic process | 118/3246 | 451/18723 | 1.30e-06 | 2.39e-05 | 118 |
GO:004348715 | Prostate | Tumor | regulation of RNA stability | 54/3246 | 170/18723 | 3.00e-06 | 4.95e-05 | 54 |
GO:190331314 | Prostate | Tumor | positive regulation of mRNA metabolic process | 41/3246 | 118/18723 | 3.86e-06 | 6.18e-05 | 41 |
GO:001714812 | Prostate | Tumor | negative regulation of translation | 71/3246 | 245/18723 | 4.08e-06 | 6.51e-05 | 71 |
GO:190136114 | Prostate | Tumor | organic cyclic compound catabolic process | 124/3246 | 495/18723 | 7.37e-06 | 1.10e-04 | 124 |
GO:001943914 | Prostate | Tumor | aromatic compound catabolic process | 118/3246 | 467/18723 | 7.92e-06 | 1.17e-04 | 118 |
GO:006101414 | Prostate | Tumor | positive regulation of mRNA catabolic process | 30/3246 | 87/18723 | 8.61e-05 | 8.53e-04 | 30 |
GO:006115714 | Prostate | Tumor | mRNA destabilization | 29/3246 | 84/18723 | 1.09e-04 | 1.04e-03 | 29 |
GO:005077914 | Prostate | Tumor | RNA destabilization | 29/3246 | 88/18723 | 2.74e-04 | 2.25e-03 | 29 |
GO:000024512 | Prostate | Tumor | spliceosomal complex assembly | 26/3246 | 79/18723 | 5.68e-04 | 4.11e-03 | 26 |
GO:004592715 | Prostate | Tumor | positive regulation of growth | 66/3246 | 259/18723 | 5.73e-04 | 4.13e-03 | 66 |
GO:003526412 | Prostate | Tumor | multicellular organism growth | 36/3246 | 132/18723 | 2.85e-03 | 1.55e-02 | 36 |
GO:003090012 | Prostate | Tumor | forebrain development | 86/3246 | 379/18723 | 4.22e-03 | 2.11e-02 | 86 |
GO:00215434 | Prostate | Tumor | pallium development | 42/3246 | 169/18723 | 8.28e-03 | 3.62e-02 | 42 |
GO:004863813 | Prostate | Tumor | regulation of developmental growth | 74/3246 | 330/18723 | 1.00e-02 | 4.20e-02 | 74 |
GO:00219875 | Prostate | Tumor | cerebral cortex development | 30/3246 | 114/18723 | 1.04e-02 | 4.34e-02 | 30 |
GO:002261329 | Skin | cSCC | ribonucleoprotein complex biogenesis | 302/4864 | 463/18723 | 5.13e-72 | 3.22e-68 | 302 |
GO:0008380112 | Skin | cSCC | RNA splicing | 263/4864 | 434/18723 | 2.45e-53 | 5.13e-50 | 263 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ELF1 | SNV | Missense_Mutation | | c.151N>G | p.Leu51Val | p.L51V | P32519 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0B4-01 | Breast | breast invasive carcinoma | Male | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
ELF1 | SNV | Missense_Mutation | | c.1248N>C | p.Gln416His | p.Q416H | P32519 | protein_coding | tolerated(0.36) | possibly_damaging(0.759) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
ELF1 | SNV | Missense_Mutation | | c.133N>G | p.Leu45Val | p.L45V | P32519 | protein_coding | deleterious(0.02) | possibly_damaging(0.678) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
ELF1 | SNV | Missense_Mutation | novel | c.740N>T | p.Ser247Phe | p.S247F | P32519 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
ELF1 | SNV | Missense_Mutation | | c.1685N>G | p.Thr562Arg | p.T562R | P32519 | protein_coding | deleterious(0.04) | benign(0.136) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ELF1 | insertion | Frame_Shift_Ins | novel | c.101_102insT | p.Ile35AsnfsTer9 | p.I35Nfs*9 | P32519 | protein_coding | | | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ELF1 | SNV | Missense_Mutation | rs766946264 | c.1472C>T | p.Ala491Val | p.A491V | P32519 | protein_coding | tolerated(0.34) | benign(0.011) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ELF1 | SNV | Missense_Mutation | rs747465409 | c.371T>C | p.Ile124Thr | p.I124T | P32519 | protein_coding | tolerated(0.05) | benign(0.165) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ELF1 | SNV | Missense_Mutation | | c.1397N>G | p.Phe466Cys | p.F466C | P32519 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ELF1 | SNV | Missense_Mutation | novel | c.700G>A | p.Glu234Lys | p.E234K | P32519 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |